|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
|
Jan 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Rethinking clinical trial endpoints in myelodysplastic syndromes.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia.
|
Feb 2019
|
Haematologica
|
aplastic anemia
|
|
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.
|
Feb 2019
|
Cancer Med
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
|
Feb 2019
|
Biol Blood Marrow Transplant.
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
|
Mar 2019
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.
|
Mar 2019
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clonal Hematopoiesis and therapy related MDS/AML
|
Mar 2019
|
Best Practice & Research. Clinical Heamatology
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
|
Mar 2019
|
National Cancer Institute
|
myelodysplastic syndromes (MDS)
|
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Mar 2019
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
